Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05744908
Other study ID # 10.01.2023/37
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date January 10, 2023

Study information

Verified date February 2023
Source Hisar Intercontinental Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To examine the relationship between symptoms and quality of life before and after oral pentosan polysulfate (PPS) treatment in cases diagnosed with interstitial cystitis/painful bladder syndrome (IC/BPS).


Description:

Demographic characteristics, medical history, clinical conditions, and laboratory and cystoscopic data of patients who applied to our clinic between January 2018 and December 2021 and were diagnosed with IC/BPS were retrospectively analyzed. Adult male and female patients with IC/BPS who received 300 mg/day PPS at least six months ago with complaints of pain, urge, frequency, and nocturia not associated with urinary tract infection were included in the study. In addition, pre- and post-treatment symptoms, ICSI scores, quality of life (scored between 1-4), and satisfaction were compared.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date January 10, 2023
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Chronic interstitial cystitis - Bladder Pain Syndrome Exclusion Criteria: - Acute cystitis - Bladder cancer - Chronic prostatitis - Bladder stone - Stress incontinence

Study Design


Intervention

Other:
Pentosan Polysulphate
300mg 3 times a day

Locations

Country Name City State
Turkey Basri Cakiroglu Istanbul
Turkey Hisar Intercontinental Hospital Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Hisar Intercontinental Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary bladder wall thickness 0.3 over 3 mm 1 under 3 mm, Three months
Primary improvement of lower urinary tract symptoms 1 if symptoms improved, 0 if not Three months
See also
  Status Clinical Trial Phase
Terminated NCT03143920 - Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder Early Phase 1
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Not yet recruiting NCT06013449 - Efficacy of Pulsed Electromagnetic Field and Heparin/Bupivacaine Instillations N/A
Not yet recruiting NCT04734106 - Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis Early Phase 1
Active, not recruiting NCT02858453 - Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Phase 3
Completed NCT01879683 - A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions Phase 1
Completed NCT04275297 - Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome N/A
Completed NCT02331472 - The Efficacy of Urine Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome (Pilot Study)
Completed NCT04540887 - PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome N/A
Recruiting NCT05149573 - Investigation of PEMF Therapy for Female Patients With IC/BPS N/A